Nope! I would switch for 2 reasons.

1) empiric GN coverage imo is because we broadly cover enteric (and pulmonary) GN when we don't have a known source or cause

2) if mssa and not mrsa, targeted therapy (cefazolin or nafcillin/ oxacillin) > nontargeted therapy (cefepime, pip tazo, meropenem)